The enhancement of liver targetability of [3H]methotrexate-galactosylated serum albumin conjugate in mice

International Journal of Pharmaceutics

Volumn 132, Issue 1-2, 1996, Pages 175-182

  Lim, Chong Rae ^a   Oh, Kyoung Hee ^a   Kim, Kyoung Mi ^a   Yuk, Soon Hong ^b   Lee, Hai Bang ^b   Kim, Chong Kook ^a  

^a Seoul National University   (South Korea)

^b Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Galactosylated serum albumin; Liver targetability; Methotrexate; 3H Methotrexate galactosylated serum albumin conjugate; 3H Methotrexate serum albumin conjugate

Indexed keywords

METHOTREXATE; METHOTREXATE DERIVATIVE; SERUM ALBUMIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG TARGETING; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL;

EID: 0029996930     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5173(95)04381-0     Document Type: Article

References (27)

1. Ashwell, G. and Harford, J., Carbohydrate receptors of the liver. Annu. Rev. Biochem., 51 (1982) 531-534.
2. Ashwell, G. and Morell, A., The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv. Enzymol., 41 (1974) 99-128.
3. Atti, A.D., Pittman, R.C. and Steinberg, D., Metabolism of native and lactosylated human low density lipoprotein: evidence for two pathways for catabolism of exogenous proteins in rat hepatocytes. Proc. Natl. Acad. Sci. USA, 77 (1980) 5923-5927.
4. Bleyer, W.A., The clinical pharmacology of methotrexate. Cancer, 41 (1978) 36-51.
5. Chabner, B.A., Mayer, C.E., Coleman, C.N. and Johns, D.G., The clinical pharmacology of antineoplastic agents. New Engl. J. Med., 292 (1975) 1107-1113.
6. Chiou, W. L., Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J. Pharmacokinet. Biopharm., 6 (1978) 539-546.
7. Chu, B.C.F. and Whiteley, J.M., High molecular weight derivatives of methotrexate as chemotherapeutic agents. Mol. Pharmacol., 13 (1977) 80-88.
8. Chu, B.C.F. and Whiteley, J.M., Control of solid tumor metastases with high-molecular-weight derivatives of methotrexate. J. Natl. Cancer Inst., 62 (1979) 79-81.
9. Dubios, M., Gilles, K.A., Hamilton, J.K., Rebers, P.A. and Smith F., Colorimetric method for determination of sugars and related substances. Anal. Chem., 28 (1956) 350-356.
10. Evans, W.E., Crom, W.R. and Yalowich, J., Applied therapeutics. In Evans, W.E., Schentag, J.J. and Jusko, W.J. (Eds.), Applied Pharmacokinetics, Principles of Therapeutic Drug Monitoring, 2nd edn., Spokane, WA, 1986, pp. 1009-1056.
11. Fiume, L., Busi, C., Mattioli, A., Balboni, P.G. and Barbanti-Brodno, G., Hepatocytes targeting of adenine-9-β-D-arabinofuranoside 5′-monophosphate (Ara-AMP) coupled to lactosaminated albumin. FEBS Lett., 129 (1981) 261-264.
12. Fiume, L., Busi, C. and Mattioli, A., Lactosaminated human serum albumin as hepatotropic drug carrier: rate of uptake by mouse liver. FEBS Lett., 146 (1982) 42-46.
13. Gregoriadis, G., Morell, A.G., Sternlieb, I. and Schenberg, I.H., Catabolism of desialylated ceruloplasmin in liver. J. Biol. Chem., 245 (1970) 5833-5834.
14. Gupta, P.K. and Hung, C.T., Quantitative evaluation of targeted drug delivery systems. Int. J. Pharm., 56 (1989) 217-226.
15. Halbert, G.W., Florence, A.T. and Stuart, J.F.B., Characterization of in-vitro drug release and biological activity of methotrexate-bovine serum albumin conjugates. J. Pharm. Pharmacol., 39 (1987) 871-876.
16. Han, J.-H., Development of liver targeting methotrexate delivery system using neo-galactosylated bovine serum albumin conjugate. Ph.D. dissertation, Seoul National University, Seoul, 1994.
17. Jacobs, S.A., D'Urso-Scott, M. and Bertino, J.R., Some biochemical and pharmacologic properties of amethopterin-albumin. Ann. New York Acad. Sci., 186 (1971) 284-286.
18. 3H-methotrexate-human serum albumin conjugates in mice. Drug Dev. Ind. Pharm., 19 (1993) 961-970.
19. Kim, C.-K. and Oh, Y.K., Development of hydrophilic human serum albumin microspheres using a drug-albumin conjugate. Int. J. Pharm., 47 (1988) 163-169.
20. Kim, C.-K., Hwang, S.-J. and Lee, M.G., The organ targetability of small and large albumin microspheres containing free and HSA conjugated methotrexate. Int. J. Pharm., 89 (1993) 91-102.
21. Kim, C.-K., Lee, M.-K., Han, J.-H. and Lee, B.-J., Pharmacokinetics and tissue distribution of methotrexate after intraveous injection of differently charged liposome-entrapped methotrexate to rats. Int. J. Pharm., 108 (1994) 21-29.
22. Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J., Protein measurement with folin phenol reagent. J. Biol. Chem., 193 (1951) 265-275.
23. Sato, Y., Kiwada, H. and Kato, Y., Effects of dose and vesicle size on the pharmacokinetics of liposomes. Chem. Pharm. Bull., 34 (1986) 4244-4252.
24. Schwartz, B.A. and Gray, G.R., Proteins containing reductive aminated disaccharide: synthesis and chemical characterization. Arch Biochem. Biophys., 181 (1977) 542-549.
25. Shen, D.D. and Azarnoff, D.L., Clinical pharmacokinetics of methotrexate. Clin. Pharmacokinet., 3 (1978) 1-13.
26. Yoon, E.J., Chang, H.W., Lee, M.G., Lee, H.J., Park, M.K. and Kim, C.-K., Pharmacokinetics of methotrexate after intravenous infusion of methotrexate-rabbit serum albumin conjugate to rabbits. Int. J. Pharm., 67 (1991) 177-184.
27. Wu, G.Y., Wu, C.H. and Stochert, R.J., A model for specific rescue of normal hepatocytes during methotrexate treatment of hepatic malignancy. Proc. Natl. Acad. Sci. USA, 80 (1983) 3078-3081.